Voriconazole suppresses the growth of Leishmania species in vitro

Parasitology Research

Volumn 112, Issue 5, 2013, Pages 2095-2099

  Kulkarni, Manjusha M ^a   Reddy, Niveditha ^a   Gude, Tulasi ^a   McGwire, Bradford S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b Doan N 1145 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ERGOSTEROL; FLUCONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG TARGETING; GROWTH INHIBITION; GROWTH RATE; IC 50; IN VITRO STUDY; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MICROBIAL GROWTH; NONHUMAN; PARASITE VIABILITY; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; STEROL SYNTHESIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; FLUCONAZOLE; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; LEISHMANIA; PARASITIC SENSITIVITY TESTS; PYRIMIDINES; SPECIES SPECIFICITY; TRIAZOLES;

HEXAPODA; MAMMALIA; PROTOZOA;

EID: 84876287962     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-013-3274-x     Document Type: Article

References (18)

1. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC (1999) Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother 43(12):2910-2914
2. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH (2002) Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346(12):891-895
3. Beach DH, Goad LJ, Holz GG Jr (1988) Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 31(2):149-162
4. Berman J (2003) Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16(5):397-401
5. Berman JD (1981) Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg 30(3):566-569
6. Emad M, Hayati F, Fallahzadeh MK, Namazi MR (2011) Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous Leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 64(3):606-608. doi: 10.1016/j.jaad.2010.04.014
7. Gangneux JP, Dullin M, Sulahian A, Garin YJ, Derouin F (1999) Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob Agents Chemother 43(1):172-174
8. Ginger ML, Chance ML, Goad LJ (1996) Carbon sources for fatty acid and sterol biosynthesis in Leishmania species. Biochem Soc Trans 24(3):434S
9. Goad LJ, Holz GG Jr, Beach DH (1985) Sterols of ketoconazole-inhibited Leishmania mexicana mexicana promastigotes. Mol Biochem Parasitol 15(3):257-279
10. Kulkarni MM, Jones EA, McMaster WR, McGwire BS (2008) Fibronectin binding and proteolytic degradation by Leishmania and effects on macrophage activation. Infect Immun 76(4):1738-1747
11. Laffitte E, Genton B, Panizzon RG (2005) Cutaneous leishmaniasis caused by Leishmania tropica: treatment with oral fluconazole. Dermatology 210(3):249-251
12. Marrapu VK, Mittal M, Shivahare R, Gupta S, Bhandari K (2011a) Synthesis and evaluation of new furanyl and thiophenyl azoles as antileishmanial agents. Eur J Med Chem 46(5):1694-1700. doi: 10.1016/j.ejmech.2011.02.021
13. Marrapu VK, Srinivas N, Mittal M, Shakya N, Gupta S, Bhandari K (2011b) Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents. Bioorg Med Chem Lett 21(5):1407-1410. doi: 10.1016/j.bmcl.2011.01.026
14. Paniz Mondolfi AE, Stavropoulos C, Gelanew T, Loucas E, Perez Alvarez AM, Benaim G, Polsky B, Schoenian G, Sordillo EM (2011) Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother 55(4):1774-1776. doi: 10.1128/AAC.01498-10
15. Pirson P, Leclef B, Trouet A (1990) Activity of ketoconazole derivatives against Leishmania mexicana amazonensis within mouse peritoneal macrophages. Ann Trop Med Parasitol 84(2):133-139
16. Sanati H, Belanger P, Fratti R, Ghannoum M (1997) A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41(11):2492-2496
17. Scott LJ, Simpson D (2007) Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67(2):269-298
18. Verma A, Srivastava S, Sane SA, Marrapu VK, Srinivas N, Yadav M, Bhandari K, Gupta S (2011) Antileishmanial activity of benzocycloalkyl azole oximino ethers: the conformationally constraint analogues of oxiconazole. Acta Trop 117(2):157-160. doi: 10.1016/j.actatropica.2010.10.011